The DOI matches its Crossref record, with a small difference in title or year; 40 of the 40 references it cites were found in a registry or an index.
The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial
Abstract
BACKGROUND: The clinical effect of probiotics on irritable bowel syndrome (IBS) is still controversial. AIMS: We aimed to evaluate the effects of a probiotic mixture on IBS symptoms and the composition of fecal microbiota in patients with diarrhea-dominant IBS (D-IBS). METHODS: Fifty patients with D-IBS were randomized into placebo or probiotic mixture (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, and Streptococcus thermophilus 1.0×10 CFU) groups. Treatment was taken daily for 8 weeks. The primary outcome was adequate relief (AR) of overall IBS symptoms, which was assessed weekly for 10 weeks. A responder was defined as a patient who experienced AR for at least half of the 10-week study period. Secondary outcomes included the effects on individual symptoms, stool parameters, and IBS quality of life. The fecal flora compositions were analyzed by polymerase chain reaction denaturing gradient gel electrophoresis (DGGE). RESULTS: The proportion of AR was consistently higher in the probiotics group than in the placebo group throughout the 10-week period (P<0.05). The proportion of responders was significantly higher in the probiotics group than in the placebo group (48% vs. 12%, P=0.01). Stool consistency improved significantly in the probiotics group compared with the placebo group. Percent changes in individual symptom scores were similar in the 2 groups, but IBS quality of life improvement tended to be higher in the probiotics group. Comparison of denaturing gradient gel electrophoresis profiles of fecal flora showed that the concordance rate between bacterial compositions before and after treatment was significantly higher in the probiotics group than in the placebo group (69.5% vs. 56.5%, P=0.005). CONCLUSIONS: The probiotic mixture was effective in providing AR of overall IBS symptoms and improvement of stool consistency in D-IBS patients, although it had no significant effect on individual symptoms. The therapeutic effect of probiotics is associated with the stabilization of intestinal microbiota.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two studies evaluated overall IBS symptoms as a primary end point, with one reporting a significant beneficial effect of the specific probiotic treatment compared with placebo,37 and one reporting no significant difference.38”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [37]
In the citing paper
“Two studies evaluated overall IBS symptoms as a secondary end point only, and both reported a significant beneficial effect of the specific probiotic treatments33–39”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [37]
In the citing paper
“Two studies reported no difference between specific probiotic treatments and placebo,28–37 and one study reported a significant worsening of diarrhoea with the specific probiotic treatment compared with placebo.59”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [37]
In the citing paper
“Other smaller studies reported some beneficial effects with other probiotic strains including Bifidobacterium animalis DN-173 010 (74), Bifidobacterium bifidum MIMBb75 (72), Lactobacillus plantarum 299V (117), Saccharomyces boulardii (37), and combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 (144) and multispecies probiotic mixtures (71, 87, 88).”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [87]
In the citing paper
“However, it has been suggested that probiotics might reshape the intestinal ecosystem generating an ecological milieu that is unfavorable for the growth of harmful species by increasing the number of Lactobacilli and Bifidobacteria [199] that will stabilize the intestinal microbiota [174,179] .”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [174]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448 · cited 4×
“Although no statistical differences were observed between the 2 groups in terms of IBS-QOL, the percentage change in the overall score tended to be higher in the probiotics group than in the placebo group; results from most studies evaluating QOL are similar to our results.(20,27,28,31,33) The small sample size of our…”
ResultInfluentialAGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384 · cited 2×
“Although the concept of IBS has been established for several decades, currently available therapies provide symptomatic relief at best and none of the treatments really work to alleviate symptoms consistently.(2,13) Probiotics are characterized very broadly as live microorganisms, which, when administered in adequate…”
BackgroundKassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002 · cited 9×
“Involvement of microbial factors, such as alteration in the intraluminal milieu, has also been suggested in the pathophysiology of IBS.(8,9) Alterations in the composition of fecal microbiota has been found in inflammatory bowel disease and in IBS.”
BackgroundInfluentialWhorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00734.x · Cited by 799 · cited 1×
“Each week during the treatment and posttreatment periods, patients responded to the adequate relief (AR)related question.(19) Patients visited the clinic to receive their investigational products and for an assessment of compliance, symptoms, and safety every 4 weeks after the first administration.”
MethodThe efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728 · cited 2×
“Two recent meta-analyses have suggested that probiotics may be associated with improvement in IBS symptoms.(15,16) In this study, we set out to determine the effects of a multispecies probiotic mixture on symptoms and changes in the composition of fecal microbiota in D-IBS.”
BackgroundSILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551 · cited 9×
“Diagnosis of IBS was based on Rome III criteria.17 The study was carried out in patients with D-IBS and excluded constipation-dominant IBS or mixed-type IBS.17 The inclusion criteria were men or women aged between 18 and 65 years; organic abnormality excluded by complete blood cell count, blood chemistry and colonosco…”
ResultInfluentialDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Regional cerebral activity in normal and pathological perception of visceral pain
Silverman, D., Munakata, J., Ennes, H., Mandelkern, M., Hoh, C., & Mayer, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70220-8 · Cited by 546
Niedzielin, K., Kordecki, H., & Birkenfeld, B. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200110000-00004 · Cited by 506
Cited by
Hemarajata, P., & Versalovic, J. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12459294 · Cited by 1,083
Impact of antibiotics on the human microbiome and consequences for host health
Patangia, D. V., Anthony Ryan, C., Dempsey, E., Paul Ross, R., & Stanton, C. (2022) · MicrobiologyOpen · doi:10.1002/mbo3.1260 · Cited by 754
“Probiotics are widely used for this purpose and have been shown to increase the abundance of beneficial microbes, stabilize the microbial community and thus alleviate the effects of antibiotics (Ki Cha et al., 2012; Korpela et al., 2018).”
BackgroundFord, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
Diet-Induced Dysbiosis of the Intestinal Microbiota and the Effects on Immunity and Disease
Brown, K., DeCoffe, D., Molcan, E., & Gibson, D. L. (2012) · Nutrients · doi:10.3390/nu4081095 · Cited by 676
“The therapeutic effects of probiotics are associated with the stabilization of intestinal microbiota [149].”
BackgroundFord, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Metadata
- Authors
- Ki Cha, B., Mun Jung, S., Hwan Choi, C., Song, I.-D., Woong Lee, H., Joon Kim, H., Hyuk, J., Kyung Chang, S., Kim, K., Chung, W.-S., & Seo, J.-G.
- Affiliations
- Chung-Ang University (KR)
- Cell Biotech (South Korea) (KR)
- Corresponding author
- Song, In-Do
- Hyuk, Jae
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2012-03
- Volume
- 46
- Issue
- 3
- Pages
- 220-227
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W1981993670
- Cited by
- 216
- References
- 40
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 13 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 15 · 2019: 17 · 2018: 22 · 2017: 15 · 2016: 15 · 2015: 15 · 2014: 19 · 2013: 13 · 2012: 5
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, fecal microbiota, Lactobacillus, Bifidobacterium, Streptococcus thermophilus, stool consistency, IBS quality of life
- MeSH terms
- Adult, Bifidobacterium, Diarrhea, Double-Blind Method, Feces, Female, Humans, Lactobacillus, Lactobacillus acidophilus, Male, Middle Aged, Severity of Illness Index, Species Specificity, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Streptococcus thermophilus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial. https://app.cochat.ai/papers/10.1097/mcg.0b013e31823712b1
- The paper
- Ki Cha, B., Mun Jung, S., Hwan Choi, C., Song, I.-D., Woong Lee, H., Joon Kim, H., Hyuk, J., Kyung Chang, S., Kim, K., Chung, W.-S., & Seo, J.-G. (2012). The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0b013e31823712b1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.